— Know what they know.
Not Investment Advice
Also trades as: BIOPOR.CO (CPH) · $vol 0M

THOXF OTC

BioPorto A/S
1W: +0.0% 1M: +0.0% 3M: +0.0% YTD: -48.3% 1Y: -48.3% 3Y: -58.6% 5Y: -62.8%
$0.15
+0.00 (+0.00%)
 
OTC · Healthcare · Medical - Diagnostics & Research · Tech Score Strong Sell · Power 39 · $73.8M mcap · 459M float · 0.0055% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Cap$73.8M
52W Range0.149-0.31
Volume30,000
Avg Volume25,333
Beta1.38
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOCarsten Buhl
Employees46
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2019-12-13
Tuborg Havnevej 15, st.
Hellerup, CR 2900
DK
45 45 29 00 00
About BioPorto A/S

BioPorto A/S is an in-vitro diagnostics firm that supplies diagnostic tools and antibodies globally to medical professionals and scientists. Its product portfolio includes the neutrophil gelatinase-associated lipocalin (NGAL) test – a particle-enhanced turbidimetric assay designed to quantify NGAL levels, which complements existing clinical assessments and standard diagnostic procedures. Furthermore, it supplies monoclonal antibodies for scientific, pharmaceutical, and clinical research applications, along with enzyme-linked immunosorbent assay (ELISA) kits, automated in-vitro diagnostic assays, and a versatile rapid assay device platform for developing lateral flow assays. BioPorto distributes its products through its proprietary sales force, an extensive network of distributors, and strategic OEM collaborations. Established in 2000, the company's base of operations is in Hellerup, Denmark.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms